Onconetix, Inc. (ONCO) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.20
↓-100% vs avg
5yr avg: 143.83
30Y Low16.2·High105.5
ROE
↓
-110.6%
↓+68% vs avg
5yr avg: -342.8%
30Y Low-314%·High-14%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ONCO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Onconetix, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $596410 | $256M | $303M | $593M | $2.4B | — | — | — |
| Enterprise Value | $-4575470 | $251M | $311M | $598M | $2.3B | — | — | — |
| P/E Ratio → | -0.20 | — | — | — | — | — | — | — |
| P/S Ratio | 0.73 | 313.95 | 119.92 | 10139.74 | — | — | — | — |
| P/B Ratio | 0.20 | 16.24 | 31.50 | 422.09 | 105.51 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ONCO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 307.61 | 123.41 | 10230.93 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
ONCO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Onconetix, Inc. earns an operating margin of -778.2%. Operating margins have expanded from -61634.5% to -778.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -110.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.6% | 77.6% | 41.8% | -1927.9% | — | — | — | — |
| Operating Margin | -778.2% | -778.2% | -2238.0% | -61634.5% | — | — | — | — |
| Net Profit Margin | -1721.0% | -1721.0% | -2325.2% | -63986.5% | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -110.6% | -110.6% | -1065.7% | -314.5% | -112.6% | -110.6% | -29.8% | -13.7% |
| ROA | -52.8% | -52.8% | -101.5% | -65.7% | -91.3% | -86.6% | -29.4% | -13.5% |
| ROIC | -32.8% | -32.8% | -336.9% | -1603.3% | — | — | -653.0% | — |
| ROCE | -49.4% | -49.4% | -140.8% | -77.7% | -113.1% | -110.4% | -30.2% | -14.7% |
ONCO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $5M exceeds total debt of $48774, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.98 | 7.04 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.33 | 0.92 | 3.80 | -1.15 | -1.33 | -0.91 | -1.01 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -17.68 | -17.68 | -41.44 | -54.72 | — | — | — | — |
Net cash position: cash ($5M) exceeds total debt ($48774)
ONCO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.66x is below 1.0, meaning current liabilities exceed current assets. The current ratio has improved from 0.34x to 0.66x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.66 | 0.66 | 0.05 | 0.34 | 6.69 | 1.88 | 66.94 | 79.98 |
| Quick Ratio | 0.65 | 0.65 | 0.05 | 0.32 | 6.69 | 1.88 | 66.94 | 79.98 |
| Cash Ratio | 0.57 | 0.57 | 0.04 | 0.26 | 6.57 | 1.18 | 62.75 | 79.87 |
| Asset Turnover | — | 0.03 | 0.09 | 0.00 | — | — | — | — |
| Inventory Turnover | 1.22 | 1.22 | 22.93 | 3.26 | — | — | — | — |
| Days Sales Outstanding | — | 132.89 | 13.93 | 934.78 | — | — | — | — |
ONCO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Onconetix, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 0.1% | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $3M | $113050 | $17612 | $12632 | $11372 | $11372 | $11372 |
Peer Comparison
Compare ONCO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ONCOYou | $596410 | -0.2 | — | — | 77.6% | -778.2% | -110.6% | -32.8% | — |
 CRVS | $1B | -23.7 | — | — | — | — | -32.6% | -78.1% | — |
 AGEN | $127M | -894.1 | — | — | 29.6% | -18.0% | — | — | — |
 IMVT | $8B | -13.8 | — | — | — | — | -64.8% | — | — |
 NUVL | $9B | -21.1 | — | — | — | — | -36.7% | -32.5% | — |
 PRAX | $9B | -22.5 | — | — | — | — | -45.8% | -65.0% | — |
 JANX | $875M | -7.8 | — | — | 79.7% | -1576.7% | -11.5% | -15.3% | — |
 ARCC | $13B | 9.6 | 12.7 | 11.2 | 75.7% | 69.7% | 9.4% | 5.7% | 7.3 |
 ORIC | $924M | -6.1 | — | — | — | — | -41.3% | -39.9% | — |
 TELA | $36M | -1.0 | — | — | 67.7% | -42.0% | -223.4% | -169.0% | — |
 CLPT | $512M | -19.0 | — | — | 61.4% | -65.4% | -95.6% | -73.7% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ONCO — Frequently Asked Questions
Quick answers to the most common questions about buying ONCO stock.
What is Onconetix, Inc.'s P/E ratio?
Onconetix, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
What is Onconetix, Inc.'s ROE?
Onconetix, Inc.'s return on equity (ROE) is -110.6%. The historical average is -115.3%.
Is ONCO stock overvalued?
Based on historical data, Onconetix, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Onconetix, Inc.'s profit margins?
Onconetix, Inc. has 77.6% gross margin and -778.2% operating margin.